Acute myeloid leukemia following organ transplantation (PT-AML) is a rare event with only a few published cases in the literature. We present three patients who developed AML (FAB M1, M5, M4) after renal, double lung or liver transplantation. Molecular analysis detected a t(9;11) in one patient and documented the recipient origin of AML in a second patient. All patients were treated with chemotherapy. Immunosuppression was reduced to cyclosporin A (CsA) and prednisone in two patients and to prednisone alone in one patient. Two patients achieved a complete remission (CR), with a remission duration of 4.6 months in one patient, the other patient died from septicemia after 15.2 months in CR. One patient was refractory to chemotherapy and died from septicemia. This report together with the documented cases in the literature suggests that PT-AML (1) develops after a median interval of 5 years after transplantation with variable latency (range, Ͻ1-17 years); (2) is heterogeneous with respect to FAB classification; (3) shows chromosomal and molecular changes typical of therapy-related AML (t-AML: −7, +8, 11q23, inv16, t(15;17)); (4) standard chemotherapy is feasible after reduction of immunosuppression and produces a CR rate of 56% with a median remission duration of 4.6 months and an overall survival of 2.6 months; (5) the major complications are early death (25%), Gram-negative septicemia, progressive disease or relapse. This review provides diagnostic and therapeutic experiences and guidelines for the management of this increasing group of post-transplant patients.
Introduction
The development of neoplasias as a consequence of immunosuppressive therapy is a significant complication of organ transplantation. [1] [2] [3] Patients with heart or lung allografts receiving intensive immunosuppressive therapy with CsA, azathioprine and prednisone are especially at risk. 3, 4 The most common post-transplant malignancies are lymphoproliferative disorders (non-Hodgkin lymphomas of B cell origin) and solid tumors. [4] [5] [6] AML following solid organ transplantation is less frequent. 7, 8 Several cases with AML post-renal transplantation have been published. 7, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] One patient with AML out of a series of 124 cardiac allograft recipients has been reported. 20 AML as a complication of lung or liver transplantation has not been described yet. The therapeutic options for all of these malignancies are hampered by a high therapy-related mortality, which is due to poor hematologic tolerance to chemotherapy, as well as to frequent infections resembling those in other immunocompromised patients. 21 We report on AML in three allograft recipients treated with induction chemotherapy regimens. Possible implications on the chemotherapeutic, anti-infectious and immunosuppressive management of comparable cases are discussed.
Patient 1
A 56-year-old man received a sequential bilateral lung transplant for secondary emphysema caused by chronic obstructive pulmonary disease in June 1993. The early postoperative course was uneventful. Immunosuppressive therapy consisted of induction therapy with antithymocyte globulin (ATG) and a triple-drug regimen with CsA, azathioprine and prednisone. An aspergilloma in the middle lobe of the right lung 1 month after transplantation was successfully treated with intravenous amphotericin B. The patient received pneumocystis prophylaxis with sulfamethoxazole/trimethoprim. In March 1994, readmission was necessary because of diarrhea and septicemia with Klebsiella pneumoniae. The white blood cell count (WBC) was 6.3 × 10 9 /l with 22% neutrophils, 6% bands, 26% lymphocytes, 6% mature monocytes and 40% blast cells. The pretreatment characteristics are summarized in Table 1 . Bone marrow aspiration showed leukemic infiltration with 72% large monoblastic cells. The blasts stained positive for alpha-naphthyl-acetate esterase but negative for myeloperoxidase. Serum and urine lysozyme levels were 123.1 mg/dl and 760 mg/dl, respectively. The leukemia was therefore classified as M5a according to the FAB classification. 22 The blast cell immunophenotype was: CD13±, CD33+, CDw65+, CD15±, CD14−, HLA-DR+, CD64+, CD56+, CD34−, corresponding to an immature monoblastic population. No 11q23 rearrangement could be detected by Southern blot analysis, a cytogenetic analysis was not possible due to a lack of growth. Genomic fingerprinting was performed (in retrospect) to clarify the origin of the leukemic cells: DNA from bone marrow slides at diagnosis and in remission were examined by PCR. 23 All four systems (THOI, TPOX, vWF, F13) used confirmed that the monoblastic population was of recipient origin corresponding to the pattern obtained from normal blood cells of the patient in remission. Induction chemotherapy consisting of daunorubicin (45 g/m 2 , days 1-3), cytosine arabinoside (2 × 100 mg/m 2 , days 1-7), and etoposide (100 mg/m 2 , days 1-5) was administered. Immunosuppression was reduced to 10 mg prednisone, CsA dose was adjusted to plasma levels of approximately 100 ng/ml, azathioprine was discontinued (Figure 1 ). The patient received daily antibiotic prophyaxis with norfloxacin (2 × 400 mg) and antifungal prophylaxis with fluconazole (1 × 200 mg). In order to reduce the time of aplasia, granulocyte colony-stimulating factor (G-CSF; 300 g/day) was given from day 8 to day 24 after informed consent. During aplasia, the patient had a septice- . Supportive care and G-CSF were administered as during induction therapy. The chemotherapy was accompanied by aplasia until day 19 and complicated by 5 days of fever due to septicemia with Enterococcus faecalis which responded to piperacillin and vancomycin. Because of septic complications during induction and consolidation, the patient received no further chemotherapy. The last bone marrow aspiration in September 1994 showed a complete remission with 3% blast cells. In May 1995 the immunosuppressive treatment consisting of CsA and prednisone was intensified by addition of azathioprine because of a decrease in FEV1. Subsequently the patient did well until the end of July 1995, when he developed dyspnea, fever, and thoracic pain. Spiral computed tomographic scanning showed a round opacity in the area of the left hilus without presence of lymphadenopathy. The histologic examination showed no evidence of malignancy, Pseudomonas aeruginosa was cultured from bronchial washing specimen. Subsequently the patient developed septicemia and died from septic death despite intensive antibiotic and antimycotic treatment. At this time there was no clinical evidence of leukemia, postmortem bone marrow was not available.
Patient 2
A 65-year-old man received a liver graft for multicentric hepatocellular carcinoma and liver cirrhosis post-hepatitis C in June 1991. Post-transplant he was started on an induction course of ATG and prednisone. On the eighth postoperative day a histologically proven rejection grade II occurred and was successfully treated with 3 days of methylprednisone bolus therapy. The further post-transplant course was uneventful. Immunosuppressive medication at the time of discharge was a triple therapy regimen consisting of prednisone, CsA and azathioprine. Seven weeks later the patient received another methylprednisone bolus therapy because of a second grade I rejection episode. Subsequently the patient did well until October 1997, when he was admitted because of recurrent dyspnea due to atrial fibrillation and mitral regurgitation.
By that time the WBC was 187 × 10 9 /l with 69% blast cells, 22% partly immature monocytes, 3% promyelocytes, 2% myelocytes and 4% lymphocytes in the differential count (Table 1) . Serum and urine lysozyme levels were elevated to 450 mg/dl and 7.8 mg/dl, respectively. Bone marrow aspiration showed a hypercellular marrow with 72% of blast cells containing Auer rods in their cytoplasm and 11% immature monocytes. Eosinophils were Ͻ1%. With myeloperoxidase 86% of the non-erythropoietic cells (predominantly blast cells) stained positive, 25% of the non-erythropoietic cells stained positive for alpha-naphthyl-acetate esterase. The blast cell immunophenotype was: CD13+, CD33−, CDw65−, CD14+, CD15−, HLA-DR+, CD11b+, CD64−, CD34−, TdT−. Based on these findings the diagnosis of AML, FAB M4 was established. Cytogenetic analysis revealed a normal 46 XY karyotype. No 11q23 rearrangement could be deteced by Southern blot analysis. With the exception of prednisone the immunosuppressive treatment was discontinued. The patient received the same antibiotic prophylaxis as patient 1. A cytoreductive therapy with hydroxyurea was started. Subsequently the WBC decreased to 15.6 × 10 9 /l within 4 days. The patient developed a severe tumor lysis syndrome with disseminated intravascular coagulation, acute renal as well as hepatic failure, and deterioration of general condition. After recovery from the tumor lysis syndrome induction therapy with intermediate-dose Ara-C (2 × 1 g/m 2 on days 1, 3 and 5) was begun. The day 5 dose of Ara-C had to be omitted because of an increase of total bilirubin to 7 mg/dl. G-CSF (300 g/day) was given from day 6 to day 12. On day 14 the WBC increased to 6.1 × 10 9 /l and 49% blast cells emerged in the differential count, indicating a resistant disease. In order to prevent a rapid increase of the blast cells the patient received hydroxyurea temporarily for 5 days. On day 22 a second induction chemotherapy course with intermediate-dose Ara-C was delivered. During aplasia the patient developed a Pseudomonas aeruginosa septicemia and despite aggressive antibiotic and supportive treatment he died from septicemia on day 43 of hospitalization. Postmortem histological examination of the liver showed no signs of rejection, the examination of the bone marrow showed persistence of leukemia.
Patient 3
In October 1989, a 67-year-old man received a cadaver renal allograft for end-stage renal disease secondary to diabetes mellitus. In the early postoperative course the patient was treated with 3 days of methylprednisone bolus therapy and a course of ATG because of a clinically suspected acute rejection. In January 1990, the patient once more received 3 days methylprednisone bolus therapy because of a rejection. Apart from complications due to his diabetes, the patient remained in good health with good renal function for 6 years. In a routine follow-up in January 1996 a peripheral blood smear showed 57% blast cells, 30% segmented neutrophils, 1% monocytes, 12% lymphocytes (Table 1) . Bone marrow aspiration showed 62% of blast cells with 9% remaining, dysplastic myelopoietic cells. 15% of the non-erythropoietic cells (including Ͼ3% blast cells) stained positive for myeloperoxidase and 7% stained positive for alpha-naphthyl-acetate esterase. The leukemia was classified as M1. The blast cell immunophenotype was: CD13+, CD33+, CD34+, HLA-DR+, c-kit+, CD14−, CD15−, CDw65−, CD10−, CD19−, CD2−, CD7−, CD56−, CD61−, TdT−, corresponding to an immature myeloid blast cell population. Cytogenetic analysis revealed a t(9;11)(p21;q23), a 11q23 rearrangement was detected by Southern blot analysis and by PCR AF9-MLL1 could be amplified. The creatinine was 1.76 mg/dl and the BUN 47.3 mg/dl. The patient received induction chemotherapy with intermediate-dose Ara-C. The immunosuppressive therapy was switched from azathioprine and prednisone to CsA and prednisone. Because of fluid retention and increasing CsA levels hemodialysis was necessary. An episode of fever of unknown origin responded to antibiotic treatment. A complete remission with Ͻ3% blast cells and normocellular bone marrow was documented on day 28 by bone marrow aspiration. The immunosuppressive medication at the time of discharge consisted of azathioprine and prednisone. In March 1996, the patient received one course of consolidation chemotherapy consisting of daunorubicin 45 mg/m 2 (days 1-2), etoposide 100 mg/m 2 (days 1-4), and cytosine arabinoside 2 × 100 mg/m 2 (days 1-4). Once again hemodialysis was necessary. During aplasia the patient developed fever and received antibiotic treatment with piperacillin + tazobactam, and G-CSF (300 g/day). The immunosuppressive therapy was switched to CsA and prednisolone during aplasia. In June 1996, the patient developed thrombocytopenia and leukopenia with 4% blast cells in the differential count. Bone marrow aspiration confirmed the suspected relapse with 20% blast cells. In October 1996, the patient died at home.
Epstein-Barr virus (EBV) serology, immunhistochemistry and in situ hybridization
EBV-serology was consistent with past infection (or asymptomatic reactivation) in all three patients. By in situ hybridization with fluorescein-labelled oligonucleotides complementary to EBER 1/2 and immunhistochemistry using the antibody LMP-1 no EBV genome or protein in the AML blasts of our patients was detectable (Table 1) .
Discussion
We report three cases of AML developing after renal, doublelung or liver transplantation. While there are several reports on AML following renal transplantation, AML after lung or liver transplantation has not been described yet. Molecular analysis in our patients showed an AF9-MLL1 rearrangement by RT-PCR in one patient. In a second patient who was informative for several genomic fingerprinting systems, we could show that the leukemia was of recipient origin. All three patients received induction chemotherapy which resulted in two CRs lasting for 4.6 months in one patient and 15.2 months in the other patient who then died from septicemia. The three patients survived 16.2, 1.2 and 8.7 months.
The increasing number of organ transplantations makes it likely that acute leukemia will be seen by hematologists more frequently. In order to provide some diagnostic and therapeutic guidelines we have reviewed the few well documented cases given in Table 2 . The following conclusions can be drawn from these data.
Frequency, pathogenesis, and latency
Leukemia was estimated to occur in 0.2-2.5% of all transplant recipients.
1,2,3,7 Almost all documented cases occurred after renal transplantation, probably due to the large number and good long-term outcome of these patients. In analogy to other post-transplant malignancies developing at higher frequencies in patients who receive CsA or more aggressive immunosuppression (triple therapy), one would expect relatively more AMLs after lung or cardiac transplantation. However, the few available data do not allow this conclusion. Although there is some evidence for the association of AML with azathioprine therapy, 1, 18, 24, 25 there is no real proof for the direct involvement of immunosuppression in the pathogenesis. However, the cytogenetic and molecular findings in PT-AML resemble closely the aberrations found in t-AML after chemotherapy. [26] [27] [28] [29] [30] A karyotype was available in 12/19 patients ( Table 2 ), nine of whom had clonal abnormalities including trisomy 8, loss or deletions of chromosome 7, a t(9;11), a t(15;17), or an inv (16) . 28 Interestingly, 16 of the 19 patients had received azathioprine which has been shown to be mutagenic in patients with rheumatic diseases. 31 In contrast to post-transplant lymphoproliferative disorder (PT-LPD), where immunosuppression followed by EBV-infection is causative, 5 PT-AML could rather be a direct consequence of drug toxicity. In a recent report, Leblond et al 32 showed that EBV-negative PT-LPDs also have a latency of 5 years with most patients receiving azathioprine. As expected, we did not find EBV genome or protein in the AML cells of our patients. It appears that AML develops at a 100-1000-fold higher frequency following transplantation than in the normal population (2-4 new annual cases per 100 000) 33 due to reduced immunosurveillance. In patients with certain primary disorders of the immune system an incidence of 13% of acute leukemia has been reported, although acute myeloid leukemia is rare. [34] [35] [36] In HIV-infected patients, there are a few reports on occurrence of acute myeloid leukemia, but the frequency is not greater than in the general population. 37, 38 Morphologically there is no predominance of a specific FAB subtype in PT-AML which is in accordance with the immunophenotypic and cytogenetic heterogeneity. The leukemias can present with leukopenia, as well as leukocytosis (median WBC at diagnosis 9.8 × 10 9 /l; range 0.9-187 × 10 9 /l). AML can occur at any time after transplantation starting as early as 2 months up to 17 years with a median latency period of 5 years.
Chemotherapy, immunosuppression, infections and outcome
Induction chemotherapy regimens (anthracyline + Ara-C; high-or intermediate-dose ARA-C alone) were administered to 16 of the 19 patients. At the same time azathioprine was discontinued. CsA was either discontinued or low levels of approximately 80 to 100 ng/ml were maintained (Figure 1) . Prednisone was given at doses between 10 to 40 mg/day in most patients. Acute organ rejection was only seen in one patient in whom immunosuppression was completely discontinued. 18 Chemotherapy was accompanied by an ED rate of 25%. The CR rate was 56% (9/16) with 19% non-responders. Given the fact that the chromosome pattern resembles that of t-AML these CR rates are relatively high. The problem is that this CR rate does not translate into adequate survival. This is due to a high number of deaths in CR (4/9 patients). On the other hand 5/9 patients relapsed possibly because a short consolidation treatment could be administered in only 6/9 patients. The median remission duration was 4.6 months (1.5-11). Two patients survived in second CR at the end of followup. The median overall survival of patients receiving therapy was 2.6 months (4.5 months without early deaths). The overall survival of patients who received no chemotherapy was 0.5 months.
Gram-negative infection was the most frequent complication during chemotherapy despite antibacterial and antimycotic prophylaxis. During induction chemotherapy all patients (n = 12), for whom sufficient data were available, developed infectious complications: septicemia (n = 4), fever of unknown origin (n = 4), pneumonia (n = 2), and fungal infections (n = 4). During consolidation therapy 6/7 patients had fever due to septicemia (n = 2), pneumonia (n = 2) and of unknown origin (n = 3). One patient was afebrile during consolidation therapy. Pseudomonas aeruginosa was the most frequent bacterium observed in Gram-negative septicemia and Staphylococcus spp the most frequent bacteria observed in Gram-positive septicemia. Among (invasive) fungal infections either Candida spp or Aspergillus spp were the major pathogens. Our patients were given fluconazole and norfloxacin prophylaxis together with G-CSF-support 39, 40 after the end of chemotherapy. There is little information on antibiotic and antimycotic prophylaxis regimen in the few cases reported to the literature. One patient received co-trimoxazole, colistine and itraconazole together with G-CSF (after the end of chemotherapy). 9 These combined experiences show that chemotherapy is feasible in patients with PT-AML, and that a CR rate of approximately 50% can be achieved. The poor outcome is mainly due to relapse and to infections even in CR. Since regular immunosuppression was reinstituted in most patients after the end of chemotherapy a rigid anti-infectious prophylaxis may improve the prognosis of these patients.
